Pfizer lifts full-year guidance after robust third-quarter results
Pfizer reported third-quarter revenue of $16.6 billion, largely unchanged from a year earlier. Excluding Comirnaty and Paxlovid, revenue grew 7% operationally.
The US pharma giant posted third-quarter revenues of $16.6bn, largely unchanged on the same period a year earlier, weighed down by sliding sales of Covid vaccine Comirnaty and antiviral treatment Paxlovid. Once they were stripped out, however, revenues grew 7% operationally, with especially good pe…